tert-butyl (2S)-2-(1,3-benzothiazol-2-ylcarbonyl)-pyrrolidine-1-carboxylate | 272129-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: tert-butyl (2S)-2-(1,3-benzothiazol-2-ylcarbonyl)-pyrrolidine-1-carboxylate
• 英文别名: 2-[Boc-L-Pro]benzothiazole；tert-butyl (2S)-2-(1,3-benzothiazole-2-carbonyl)pyrrolidine-1-carboxylate
• CAS: 272129-64-3
• 化学式: C₁₇H₂₀N₂O₃S
• 分子量: 332.423
• InChiKey: OEKGFPZHWWTJKN-LBPRGKRZSA-N

物化性质

• 沸点：
  471.2±55.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  87.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (2S)-2-(1,3-benzothiazol-2-ylcarbonyl)-pyrrolidine-1-carboxylate 在 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 生成 (2S,3aS,7aS)-2-[(S)-2-(Benzothiazole-2-carbonyl)-pyrrolidine-1-carbonyl]-octahydro-indole-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  酮吡咯烷和酮氮杂环丁烷作为有效的二肽基肽酶IV（DPP IV）抑制剂。

  摘要：

  在本文中，讨论了两类基于亲电子试剂的二肽基肽酶IV（DPP IV）抑制剂，酮吡咯烷和酮氮杂环丁烷的合成和构效关系（SAR）。这些系列的SAR表明，2-噻唑，2-苯并噻唑和2-吡啶基酮是针对DPP IV效力的最佳S1'结合基团。此外，环己基甘氨酸（CHG）和八氢吲哚羧酸酯（OIC）均是每个系列中最有效的S2结合基团。在中心环的α位的立体化学与酮吡咯烷系列中的效力有关，但与酮氮杂环丁烷系列中的效力无关。最后，酮氮杂环丁烷比相应的酮吡咯烷烷显示出增强的稳定性，同时保持它们的效力。实际上，

  DOI：

  10.1016/j.bmcl.2004.08.057
• 作为产物：
  描述：

  苯并噻唑 、 N-(叔丁氧基羰基)-L-脯氨酸-N′-甲氧基-N′-甲酰胺 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以53.5%的产率得到tert-butyl (2S)-2-(1,3-benzothiazol-2-ylcarbonyl)-pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity

  摘要：

  Prolycarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC(50) values of 1 and 2 nM and is not active (IC(50) > 25 mu M) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a reduction in PrCP KO mice.

  DOI：

  10.1021/jm101013m

文献信息

• Synthesis and activity of pyrrolidinyl- and thiazolidinyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oligopeptidase from Trypanosoma cruzi
  作者：Roger Joyeau、Chanfi Maoulida、Cindy Guillet、François Frappier、Antonio R.L. Teixeira、Joseph Schrével、Jaime Santana、Philippe Grellier

  DOI：10.1016/s0223-5234(00)00118-5

  日期：2000.2

  Pyrrolidinyl- and thiazolidinyl- dipeptide derivatives, featuring either a vinyl sulfone-, a 2-ketobenzothiazole-, a nitrile-, or a benzimidazole group at the C-terminus, were designed and synthesized as potential inhibitors of the prolyl-specific Tc80 proteinase from Trypanosoma cruzi, the agent of Chagas' disease. These compounds were evaluated in vitro towards the target enzyme which was classified as a serine protease belonging to the prolyl oligopeptidase family (EC 3.4.21.26). A peptidyl nitrile and two peptidyl alpha-ketobenzothiazoles were shown to be potent reversible and competitive inhibitors of Tc 80 proteinase, with K-i values in the range 38-219 nM, and compared advantageously with some known mammalian prolyl oligopeptidase inhibitors. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
• NOVEL COMPOUNDS
  申请人：Heiser Ulrich

  公开号：US20100273835A1

  公开（公告）日：2010-10-28

  The invention provides compounds of general formula (I) or a pharmaceutically acceptable salt, polymorph or solvate thereof, including all tautomers and stereoisomers thereof, wherein K, W, X; Y and Z are described throughout the description and claims. The compounds of the present invention are useful as inhibitors of prolyl endopeptidase (PEP, EC 3.4.21.26) and/or IL-6.
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：PROBIODRUG AG

  公开号：WO2009007415A2

  公开（公告）日：2009-01-15

  The invention provides compounds of general formula (I) or a pharmaceutically acceptable salt, polymorph or solvate thereof, including all tautomers and stereoisomers thereof, wherein K, W, X; Y and Z are described throughout the description and claims. The compounds of the present invention are useful as inhibitors of prolyl endopeptidase (PEP, EC 3.4.21.26) and/or IL-6.
• Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity
  作者：Changyou Zhou、Margareta Garcia-Calvo、Shirly Pinto、Matthew Lombardo、Zhe Feng、Kate Bender、KellyAnn D. Pryor、Urmi R. Bhatt、Renee M. Chabin、Wayne M. Geissler、Zhu Shen、Xinchun Tong、Zhoupeng Zhang、Kenny K. Wong、Ranabir Sinha Roy、Kevin T. Chapman、Lihu Yang、Yusheng Xiong

  DOI：10.1021/jm101013m

  日期：2010.10.14

  Prolycarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC(50) values of 1 and 2 nM and is not active (IC(50) > 25 mu M) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a reduction in PrCP KO mice.
• Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors
  作者：Dana Ferraris、Yao-Sen Ko、David Calvin、Tiffany Chiou、Susan Lautar、Bert Thomas、Krystyna Wozniak、Camilo Rojas、Vincent Kalish、Sergei Belyakov

  DOI：10.1016/j.bmcl.2004.08.057

  日期：2004.11

  In this paper, the synthesis and structure-activity relationships (SAR) of two classes of electrophile-based dipeptidyl peptidase IV (DPP IV) inhibitors, the ketopyrrolidines and ketoazetidines, is discussed. The SAR of these series demonstrate that the 2-thiazole, 2-benzothiazole, and 2-pyridylketones are optimal S1' binding groups for potency against DPP IV. In addition, both cyclohexyl glycine (CHG)

  在本文中，讨论了两类基于亲电子试剂的二肽基肽酶IV（DPP IV）抑制剂，酮吡咯烷和酮氮杂环丁烷的合成和构效关系（SAR）。这些系列的SAR表明，2-噻唑，2-苯并噻唑和2-吡啶基酮是针对DPP IV效力的最佳S1'结合基团。此外，环己基甘氨酸（CHG）和八氢吲哚羧酸酯（OIC）均是每个系列中最有效的S2结合基团。在中心环的α位的立体化学与酮吡咯烷系列中的效力有关，但与酮氮杂环丁烷系列中的效力无关。最后，酮氮杂环丁烷比相应的酮吡咯烷烷显示出增强的稳定性，同时保持它们的效力。实际上，